Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14F2N4S |
| Molecular Weight | 320.36 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(CCSC(N)=N1)C2=CC(=C(F)C=C2F)C3=CN=CN=C3
InChI
InChIKey=MJQMRGWYPNIERM-HNNXBMFYSA-N
InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1
| Molecular Formula | C15H14F2N4S |
| Molecular Weight | 320.36 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22090477
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090477
LY2811376 is a non-peptide inhibitor of BACE1 selective over BACE2. It showed robust central reduction of amyloid-β in humans.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090477
Curator's Comment: # Eli Lilly
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090477 |
240.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/show/NCT00838084
IN phase I studies LY2811376 was administered to healthy volunteers as oral capsules in a doses ranging from 5mg up to 500 mg once a day or twice a day for 1 day in up to 3 periods.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090477
Human BACE1 was cloned, expressed, and purified, and assayed using a synthetic peptide in a FRET format or using a MBP–C125Swe polypeptide substrate assay.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:09:58 GMT 2025
by
admin
on
Tue Apr 01 17:09:58 GMT 2025
|
| Record UNII |
UR18YJ97SJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UR18YJ97SJ
Created by
admin on Tue Apr 01 17:09:58 GMT 2025 , Edited by admin on Tue Apr 01 17:09:58 GMT 2025
|
PRIMARY | |||
|
1194044-20-6
Created by
admin on Tue Apr 01 17:09:58 GMT 2025 , Edited by admin on Tue Apr 01 17:09:58 GMT 2025
|
PRIMARY | |||
|
DTXSID10658051
Created by
admin on Tue Apr 01 17:09:58 GMT 2025 , Edited by admin on Tue Apr 01 17:09:58 GMT 2025
|
PRIMARY | |||
|
DB13065
Created by
admin on Tue Apr 01 17:09:58 GMT 2025 , Edited by admin on Tue Apr 01 17:09:58 GMT 2025
|
PRIMARY | |||
|
44251605
Created by
admin on Tue Apr 01 17:09:58 GMT 2025 , Edited by admin on Tue Apr 01 17:09:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|